Alvotech  (ALVO)
Other Ticker:  
Price: $12.7300 $0.23 1.840%
Day's High: $13.01 Week Perf: 7.15 %
Day's Low: $ 12.40 30 Day Perf: -17.28 %
Volume (M): 378 52 Wk High: $ 18.00
Volume (M$): $ 4,807 52 Wk Avg: $10.60
Open: $12.50 52 Wk Low: $6.70

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 66
 Capital Exp. (TTM) (Millions $) 33


   Company Address: 9 Luxembourg 1273
   Company Phone Number: 422 4500   Stock Exchange / Ticker: NASDAQ ALVO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

'FDA Approves SELARSDI: A New Chapter in Psoriasis Treatment, Spearheaded by Alvotech and Teva'

Published Tue, Apr 16 2024 9:30 PM UTC

In a significant step for psoriasis treatment, Alvotech and the U.S division of Teva Pharmaceutical Industries Ltd recently received a nod of approval from the U.S. Food and Drug Administration (FDA) for their innovative drug, SELARSDI (ustekinumab-aekn). The FDA approval acknowledges the drug as a biosimilar to Stelara (ustekinumab), widely recognized for its effectiveness ...


Alvotech Boosts Share Capital with $15.98 Issued Shares to Drive Biotech Growth

Published Fri, Mar 22 2024 8:15 PM UTC

Alvotech Increases Own Shares with $15.98 Issuance Price to Grow Share Capital
Alvotech, a leading biotech company specializing in biosimilar medicines, has announced a significant increase in its own shares. The company has issued thirteen million ordinary shares to its subsidiary, Alvotech Manco ehf., increasing its share capital by $130,000. This move comes as Alvotec...


Alvotech's Strong Financial Results and Promising Pipeline Position the Company as a Leader in Biosimilar Medicines

Published Wed, Mar 20 2024 8:15 PM UTC

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines, has recently released its financial results for the full year 2023. The company also provided an update on its pipeline and highlighted its recent corporate achievements.In terms of financial performance, Alvotech reported strong results for the year 2023. The company ...


Alvotech Set to Unveil Encouraging Full-Year 2023 Financial Results as it Continues to Advance Global Biosimilar Medicine Development

Published Tue, Mar 5 2024 9:01 PM UTC

Alvotech, a leading biotech company focused on developing and manufacturing biosimilar medicines, is preparing to announce its full-year 2023 financial results. With its commitment to providing patients worldwide with affordable and accessible treatments, Alvotech has become a key player in the global pharmaceutical industry. As investors eagerly await the release of these f...


Alvotech Sells 10 Million Shares to Investors for $166 Million, Shareholders Brace for Impact on Stock Price

Published Mon, Feb 26 2024 9:25 AM UTC

Alvotech Announces Sale of Ordinary Shares to Investors Worth $166 Million, Impact on Shareholders Explored
REYKJAVIK, Iceland, Feb. 26, 2024 - Alvotech, a leading biotech company focusing on biosimilar medicines, revealed today that it has agreed to sell 10,127,132 of its ordinary shares to investors for a total value of approximately USD 166 million. The purchase price...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com